Hidden Menace

Curing HIV means finding and eradicating viruses still lurking in the shadows.

By , , and | May 1, 2015

© JUSTIN GABBARD

Since the early 1980s, when HIV was first identified, our knowledge of the virus—how it causes disease, how it interacts with our immune system, how it responds to drugs—has grown year by year. Drugs specifically designed to target HIV, and given as a cocktail of different agents—known as combination antiretroviral therapy (ART)—have decreased the mortality associated with HIV infection to the point where, for newly diagnosed individuals today, life expectancies are comparable to those who are HIV-negative.

But of the 35 million people currently living with HIV, the World Health Organization estimates that only around 40 percent use ART, partly because about half do not know they are infected. Providing ART to all who need it is a major challenge, and even when the drugs are available they are not a panacea. Regardless of treatment, there is increasing evidence that HIV-infected individuals may be at greater risk of non-AIDS comorbidities, for example, cardiovascular disease and dementia. Moreover, ART has to be taken for life: if the drugs are stopped, virus production quickly ramps up and the disease can progress, a phenomenon known as rebound.

Rebound occurs because HIV forms a reservoir in long-lived T cells that persists despite treatment. As with all retroviruses, a key aspect of the HIV replication cycle is the reverse transcription of the viral genome into DNA, followed by integration of this viral DNA, known as the provirus, into the host genome. (See illustration.) In activated cells, this proviral DNA can give rise to viral mRNA, proteins, and infectious viral particles. However, in some infected cells, the virus enters a resting state, termed latent infection, in which transcription or translation is restricted but integrated HIV is still present. These latently infected cells make up the HIV reservoir and, eventually, may be stimulated to produce infectious virus.

One challenge in targeting latently infected cells is that they do not produce HIV antigens and are therefore indistinguishable from uninfected cells.

The HIV reservoir consists largely of resting CD4+ T cells, but other cells, such as macrophages, may also contribute. In patients who have been treated for many years with ART, these latently infected cells are rare, but still present. It has been estimated that the proportion of latently infected cells capable of giving rise to rebound virus production is approximately one in a million resting CD4+ T cells in patients on ART.1 However, the difficulty of reliably measuring the reservoir means this number could be significantly higher or lower. (See “Ethical Dilemmas.”) Regardless, the HIV reservoir is a major barrier to virus eradication, and its existence raises several questions for cure strategies. Is it possible to completely eradicate latently infected cells from the body, or can we keep them silent to prevent viral rebound? Even more to the point, is it possible to prevent the reservoir from forming in the first place?

Different types of cure

HIV REPLICATION CYCLE
See full infographic: JPG
© EVAN OTO/SCIENCE SOURCE
Due to the assimilation of viral genetic elements into the host genome, researchers previously assumed that, once infection has taken hold, HIV can never be completely eliminated from the body. Yet in 2009, German clinicians announced the case of an apparent HIV cure in Timothy Ray Brown, also known as “the Berlin patient.”2 Brown underwent a bone marrow transplant following unsuccessful treatment for acute myeloid leukemia with conventional chemotherapy. The bone marrow donor selected by Brown’s clinicians was homozygous for a mutation in the CCR5 gene, preventing the expression of the CCR5 HIV coreceptor on the surface of T cells and conferring a high degree of natural resistance to HIV infection. Following the transplant, Brown ceased taking ART, and the virus did not rebound. More than six years later, researchers have been unable to find evidence of replication-competent HIV in blood or tissues from this patient; it appears that any viral reservoir has been cleared.3 Despite the exceptional circumstances surrounding this case, many believe that the Berlin patient serves as proof of concept that HIV can be cured.

Researchers have since attempted bone marrow transplants from donors carrying the same CCR5 mutation in six other cases of HIV-positive patients. Unfortunately, all of these individuals died within a year from relapsed malignancy or transplantation complications.4 In one of these individuals, rebound occurred after an HIV variant used an alternative T-cell coreceptor, CXCR4, suggesting a potential limitation to targeting only CCR5.5

In addition to preventing the spread of the virus to new cells within body, efforts to “cure” HIV have focused on reducing the size of the reservoir to achieve a remission or functional cure, in which patients could remain off therapy without rebounding, despite detectable HIV DNA in their bodies.

These cases demonstrate the intrinsic dangers and difficulties of the Berlin patient strategy, which could never be realistically scaled up to help all those infected with HIV. Interestingly, when two patients in Boston underwent bone marrow transplants using tissue from a donor carrying wild-type CCR5, their viral levels dropped to undetectable levels, both in plasma and intracellularly, and these low levels endured for several years.6 Unfortunately, viral rebound occurred within a few months of stopping ART, indicating that the CCR5 mutation was indeed critical to the Berlin patient’s cure.7 This has led researchers to another strategy to eradicate HIV: using gene therapy to turn off CCR5 expression. If successful, such a treatment could prevent additional cells from being infected with HIV, thwarting disease progression even in the presence of a viral reservoir. (See “Genome Editing Cuts Out HIV,” The Scientist, July 21, 2014.)

Early treatment, better control

While researchers have traditionally envisaged a “sterilizing cure,” in which the virus is completely eliminated from the body, this may not be necessary for controlling the infection. In addition to preventing the spread of the virus to new cells within body, efforts to “cure” HIV have focused on reducing the size of the reservoir to achieve a remission or functional cure, in which patients could remain off therapy without rebounding, despite detectable HIV DNA in their bodies.

Serving as an example of functional cure, 14 patients across France known as the VISCONTI cohort have successfully stopped ART without return of virus production, some for many years. Unlike the Berlin patient, these patients still have detectable, although small, HIV reservoirs that could serve as a future source of viral reactivation.8 Nevertheless, the fact that these patients have achieved long-term posttreatment control (PTC) could provide important clues for the development of an HIV cure.

A key factor with the VISCONTI cohort is that these individuals started treatment very soon after being infected. Although not all patients treated early are able to cease ART without rebound, several other cohorts that commenced ART during early stages of infection have also achieved varying levels of PTC. While viral rebound occurs rapidly in most individuals, between 5 percent and 15 percent of patients remain free of virus at 24 months after ART cessation.8,9 In contrast, PTC is rarely, if ever, observed among patients who commenced ART only after their CD4+ T cell counts declined below a cut-off point, suggesting that starting treatment during primary HIV infection appears to be important for controlling the virus. Further evidence for the potential of this strategy comes from the reported cure of an infant in Mississippi who, perinatally infected with HIV, commenced ART 30 hours after birth.10 Treatment was discontinued at 18 months of life, and HIV levels remained undetectable for more than a year, until rebound occurred in July 2014.11

The SPARTAC (Short Pulse Antiretroviral Therapy at HIV Seroconversion) trial put early ART to the test in a large randomized trial that ran from 2003 to 2010 across eight countries. Adults testing positive for HIV received a short course of ART within 24 weeks of seroconversion, when an HIV-specific antibody becomes detectable in the blood, resulting in delayed CD4+ T cell decline. The trial also showed that levels of HIV DNA correlated with this delay and predicted time to viral rebound, a finding that links early treatment with reduced reservoir size, possibly as a result of limiting the initial seeding of the reservoir.12,13 Because it is almost certain that a cure will be easier to achieve in patients with lower numbers of latently infected cells, it seems that early treatment will be an important part of HIV eradication strategies.

Reversing latency

As most patients are not diagnosed with acute HIV infection and are unable to initiate ART early on, treatments are also needed to deplete the HIV reservoir once it is established. One challenge in targeting latently infected cells is that they do not produce HIV antigens and are therefore indistinguishable from uninfected cells. This transcriptional silence renders these cells invisible to immune surveillance and allows persistence of provirus over time. Although counterintuitive, waking the virus from its latent state may be the key to eradicating the reservoir, by rendering reservoir cells susceptible to immune clearance and other targeted treatments. Researchers are developing strategies combining drugs to reactivate latent virus and techniques to boost immune clearance of infected cells—a so-called kick-and-kill approach.

Transcription of proviral HIV DNA is dependent on the recruitment of appropriate transcription factors to the viral 5’ long-terminal repeat (5’ LTR). As with all genes, chromatin arrangement around the site of viral integration is an important regulator of transcriptional status. High histone acetylation at the 5’ LTR is associated with an accessible chromatin structure, favoring transcription. Acetylation status is maintained by a balance between histone acetyltransferases, which act to promote acetylation, and histone deacetylases (HDACs), which decrease acetylation. HDAC inhibitors are drugs that promote nonspecific acetylation and activate cells latently infected with HIV both in vitro and in vivo.

Vorinostat is an HDAC inhibitor used to treat cutaneous T-cell lymphoma in humans. It has been shown to disrupt HIV latency in cellular models and in primary CD4+ T cells from HIV-infected patients. Trial doses of vorinostat given to HIV-infected individuals with ART-suppressed viral replication caused increases in cellular acetylation and subsequent HIV transcription, but with no evidence of rebound.14,15 In other words, the latent cell was activated enough to start the virus life cycle, but no new virions were detected. This could be due to posttranscriptional barriers to viral expression, such as mRNA degradation, or suboptimal dosing regimens. Although it is unclear what level of expression is needed to trigger immune clearance, it is presumed that at least protein expression, if not assembled virus, will be needed. Researchers at Aarhus University in Denmark have shown that two other HDAC inhibitors, panobinostat and romidepsin, have higher potency and can induce virus production in patients treated with ART.16,17 Despite reactivation of latent viruses, however, neither of these drugs resulted in decreases in reservoir size. But given the short time period of these studies and the small number of patients, this is not altogether unexpected, and the results serve as evidence that it is possible to reactivate the reservoir in vivo.

Although coun­terintuitive, waking the virus from its latent state may be the key to eradicat­ing the reservoir, by rendering reservoir cells susceptible to immune clearance and other targeted treatments.

Although HDAC inhibitors are the most widely studied class of HIV-activating drugs, several other candidates may also be able to reverse HIV latency. These include methyltransferase inhibitors, protein kinase C agonists (prostratin and bryostatin), the BET bromodomain-inhibiting molecule JQ1, and the zinc-chelating agent disulfiram. The distinct mechanisms of these agents mean that toxicities and efficacy will differ, and it is unclear which agents will be most suited for clinical use. Human trials using HDAC inhibitors and these other HIV-activating agents are exploring the effect of these drugs on viral transcription and translation, as well as the drugs’ safety and tolerability.

Even if HIV-activating agents can provide the kick needed to disrupt HIV latency, there is no evidence that this will result in clearance of the reservoir by the immune system alone. As such, it is likely that these drugs will need to be used in combination with other strategies to promote immune clearance of these cells. The RIVER (Research in Viral Eradication of HIV Reservoirs) trial, for example, is combining vorinostat with vaccination in patients on ART in the U.K. A similar study in Denmark using the HDAC inhibitor romidepsin, and a different vaccine candidate is also underway.

Putting cure into context

Significant work remains to be done in the development of a potential cure for HIV. It is an exciting time in the field, with interventional trials running in parallel with continued basic research into the mechanisms of HIV infection and pathology. In addition, a number of large observational studies of the dynamics of reservoir size are underway to understand PTC, which may provide insights into factors that predict its occurrence, the mechanisms of reservoir formation and maintenance, and the probability of rebound.

Meanwhile, several different therapeutic approaches to an HIV cure are currently under investigation. In addition to gene therapy attempting to damage the CCR5 gene or block its expression, researchers are developing therapeutic HIV vaccines. (See “Defeating the Virus.”) Antibodies with broad HIV-neutralizing capability may have some in vivo activity against the virus, and transfusions of these are being trialled. Coupled with HIV-activating drugs, these immune augmentation strategies are important early steps towards a cure.

Of course, research into an HIV cure is only one of a multitude of approaches to solving the challenges posed by this virus. Prevention, testing, treatment, and managing comorbidities remain the cornerstone of HIV management and research worldwide. Curative interventions, while exciting, are still in very early stages of development; it is unlikely that these are going to play an important role in treatment of infected patients in the near future. Despite this, the prospect of an HIV cure remains a driving force for many, and a successful cure must, in some way, address the reservoir. In this rapidly progressing field, the next few years will be crucial in determining whether clearance of the reservoir may one day be possible.

Genevieve Martin is a doctoral student in the Nuffield Department of Medicine at the University of Oxford, U.K. Matthew Pace is a postdoctoral researcher in the same department, as well as a James Martin Research Fellow at the Institute for Emerging Infections in the Oxford Martin School. John Frater holds positions at both institutions, as well as at the Oxford National Institute of Health Research Biomedical Research Centre, and is a clinician at the John Radcliffe Hospital in Oxford.

ETHICAL DILEMMAS
One problem researchers face in evaluating HIV cure strategies is measuring the size of the latent reservoir. Several assays exist to quantify the reservoir, each with significant limitations; it is likely that these assays either over- or underestimate its size. Estimates of the number of copies of proviral DNA, for example, include a large number of integrated viruses that appear to be nonfunctional. Alternatively, the assay used to measure only replication-competent copies of the virus may underestimate the true number because it cannot activate all such copies.

In the absence of robust methods for detecting latently infected cells, treatment interruption remains the sole way of testing HIV cure interventions. Ceasing therapy, however, risks resumption of HIV production and reseeding of the reservoir, which may impact disease progression and allows for transmission of the virus.

Evidence of adverse outcomes after treatment interruption comes from the SMART study, in which such interruption was associated with increased mortality, opportunistic infections, and major non-AIDS comorbidities in chronically infected patients (N Engl J Med, 355:2283-96, 2006). Importantly, the SMART study left patients untreated for long periods of time despite high levels of viremia. Researchers have not reported adverse outcomes in studies where patients were immediately placed back on therapy after viral rebound. Nevertheless, these findings highlight the need to consider both the risks and the ethical implications of this strategy. Close monitoring of patients during treatment interruption with clear plans for restarting ART need to be part of cure intervention trials.

References

  1. D. Finzi et al., “Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy,” Nat Med, 5:512-17, 1999.
  2. G. Hütter et al., “Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation,” N Engl J Med, 360:692-98, 2009.
  3. S.A. Yukl et al., “Challenges in detecting HIV persistence during potentially curative interventions: A study of the Berlin patient,” PLOS Pathog, 9:e1003347, 2013.
  4. G. Hütter et al., “More on shift of HIV tropism in stem-cell transplantation with CCR5 delta32/delta32 mutation,” N Engl J Med, 371:2437-38, 2014.
  5. L. Kordelas et al., “Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation,” N Engl J Med, 371:880-82, 2014.
  6. T.J. Henrich et al., “Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation,” J Infect Dis, 207:1694-702, 2013.
  7. T.J. Henrich et al., “Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases,” Ann Intern Med, 161:319-27, 2014.
  8. L. Hocqueloux et al., “Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection,” AIDS, 24:1598-601, 2010.
  9. S. Lodi et al., “Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion,” Arch Intern Med, 172:1252-55, 2012.
  10. D. Persaud et al., “Absence of detectable HIV-1 viremia after treatment cessation in an infant,” N Engl J Med, 369:1828-35, 2013.
  11. K. Luzuriaga et al., “Viremic relapse after HIV-1 remission in a perinatally infected child,” N Engl J Med, 372:786-88, 2015.
  12. SPARTAC Trial Investigators et al., “Short-course antiretroviral therapy in primary HIV infection,” N Engl J Med, 368:207-17, 2013.
  13. J.P. Williams et al., “HIV-1 DNA predicts disease progression and post-treatment virological control,” eLife, 3:e03821, 2014.
  14. J.H. Elliott et al., “Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy,” PLOS Pathog, 10:e1004473, 2014.
  15. N.M. Archin et al., “Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy,” Nature, 487:482-85, 2012.
  16. O.S. Søgaard et al., “The HDAC inhibitor romidepsin is safe and effectively reverses HIV-1 latency in vivo as measured by standard clinical assays,” 20th International AIDS conference, Melbourne, Australia, July 20–25, 2014.
  17. T.A. Rasmussen et al., “Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial,” Lancet HIV, 1:e13-e21, 2014.

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Comments

Avatar of: Wire_n_Wood

Wire_n_Wood

Posts: 2

May 4, 2015

Would you do a feature on HSV-1, -2 and current advances in treatments/cures?

 

Avatar of: Milton Brian

Milton Brian

Posts: 2

May 14, 2015

 

 

 

Functional Cures in HIV Patients Receiving

High Level Whole Body Hyperthermia

“A Twenty-five Year Effort”

 

 

 

Milton Yatvin (1,2,5), Alexei Suvernev (3,4,5), George Ivanov (3,4) Sergey Cheresiz (3,4)

Oregon Health & Sciences University Portland, Oregon, USA (1), Reed College Portland, Oregon, USA (2), Novosibirsk State Medical University, Novosibirsk, Russian Federation (3), Siberian Hyperthermia Institute, Novosibirsk, Russian Federation (4), WBH TEC LLC, Washington, DC, USA (5).

 

The current goal of HIV researchers and therapists is to obtain either complete or functional cures. The latter refers to the establishment of long-term remissions in the absence of therapy. Attaining that goal has been, and continues to be, blocked by the inability of current “HIV activating” drugs to activate and eliminate all the body’s reservoirs of latently infected cells. We believe that a therapy already exists which is capable of activating HIV production in latently HIV infected cells: Extreme level-whole body hyperthermia (Heatheal). Moreover, as a result of its global distribution throughout the body, this therapy has the potential to work in all reservoirs. In addition to activating the production of virus, it also enhances immune function. Thus, it is capable of producing long-term remissions and,  perhaps,a cure.

 

In1988 in an article published in Medical Hypothesis, we proposed that high level-whole body hyperthermia (HL WBH) be used to treat HIV patients (1). Unfortunately, due consideration of that hypothesis was undermined in 1990 by the NIH’s response to the work of two physicians in Atlanta, Georgia who used this therapy to treat two patients who were in the late stages of AIDS.  Unfortunately those patients lacked the immunological capacity to respond to its beneficial effects and died shortly after treatment.

 

 

Responding to that situation, the National Institute of Allergy and Infectious Diseases (NIAID) established a panel to “evaluate” the potential value of WBH in treating patients with HIV. After deliberation, the panel released the following statement: “There appears to be no clinical, immunological or virological support for the use of hyperthermia in the treatment of HIV disease or Kaposis Sarcoma. Neither does there appear to be any support for further human experimentation in this area at this time.”  In addition, the panel also referred to our Medical Hypothesis article, saying, “Yatvin’s theoretical arguments do not address the fact that following acute HIV infection, the virus is incorporated into human DNA and thus is not accessible to denaturation.” Then, on January 5, 1990 the New York Times quoted Dr. Anthony Fauci, who was then, and still remains, the Director of NIAID, on the use of WBH: “There is very little rationale for the procedure, since some laboratory experiments have shown that heat actually increased the activity of the virus rather than killing it” (2,3).

 

As a result of the failed treatments in Atlanta, the panel’s negative conclusion, and Dr. Fauci’s skepticism, there was essentially no support in the USA for further exploration of the possibilities of using WBH for treating HIV infected patients.  Nevertheless, we persisted, and in a subsequent article in Selective Cancer Therapeutics in 1991 (4), reprinted in AIDS Patient Care in 1992, with an addendum (5), we said,“ One such approach (to fighting HIV) could involve activating immunologically silent cells either by heat (HL-WBH) or various cytokines”.

 

Later, in AIDS Patient Care (6) we reported that “Heat induction of viral and Hsp proteins would overcome the ability of these quiescent cells to escape immune surveillance. Such treatment is more likely to be effective early in HIV infection because virus-specific responses of CTLs are lost in patients with advanced HIV infections”. And, in a report in Oncology (7), we said, “We believe that the current approach of trying to spare CD4+ and other HIV infected cells in individuals during the asymptomatic stage of HIV disease is counter-productive. The strategy of trying to kill diseased cells during the early stages of disease is preferable, in that it presents the possibility of eliminating an HIV latent cell infection. We believe that patients with relatively intact immune systems will be able to eliminate such unmasked cells.” (7). In making those statements we were trying to increase awareness in the field of the fact that high-level whole body hyperthermia (Heatheal) has the ability to activate virus production in latently infected cells and enhance patient immune function. Unfortunately, this approach to recognizing and dealing with the latent cell pool was not pursued until some years later (8-12).

 

Despite roadblocks, colleagues and I have continued to pursue both basic and clinical research related to HL-WBH treatment for HIV infections. In 2009 we participated in a clinical trial at the Siberian Hyperthermia Institute, Novosibirsk, the Russian Federation. It involved 30 HIV patients, 15 female and 15 male, who were naïve with respect to antiretroviral therapy (ART) prior to and throughout the trial. All had CD4+ cell counts of 400 or above at the start of the trial, indicating that they were relatively immune competent. To start, patients received three HL-WBH treatments at weekly intervals and a fourth treatment eight weeks after the third. No additional treatments were administered for the next twenty-eight weeks. At that time all patients had viral load reductions that averaged 1.8 logs (13). The remissions lasted a minimum of 200 days, which is more than 20X the remissions reported by Davey et al. after cessation of HAART (14).

 

Stimulation of immune function, as well as reactivating latent HIV-1infected cells, is essential for successful eradication of virus, and exposure to Heatheal does both. It could also accomplish the following: a) up-regulation of all components of the latent HIV infected cell reservoir as a result of its “Global” distribution of heat throughout the entire body, b) induces a prolonged non-canonical up-regulation of the latent HIV infected cell pool; and c) enhances immune function, thereby enabling up-regulated cells to be recognized and eliminated by both re-invigorated and new cytotoxic T-cells. Specifically, Heatheal induces heat shock proteins, regulators of immune response that activate both innate and adaptive immunity (15- 19).

 

Finally, a report by Dowd et al. (20) supports a role for HL-WBH in modifying antibody access to relatively inaccessible viral epitopes. They showed that AbE53 neutralized mature West Nile virus in a time-and-temperature dependent manner. Because the kinetics of neutralization increased with elevated temperature, they speculated that certain classes of antibodies may function better in the context of a febrile response. Their findings are consistent with a model in which dynamic epitope motion provides an opportunity for antibodies to engage virions at otherwise inaccessible epitopes.

 

Summary

When HIV infected patients with relatively intact immune systems are exposed to a HL-WBH treatment regimen, the evidence offered above indicates that they are more likely to be able to purge the critically important, long lived, pool(s) of latently infected cells than those treated by HAART. Because of its global action, HL-WBH has the potential to exert an effect on any and all of the latent cell reservoirs. It does so as a result of its capacity to enhance immune function and up-regulate and prolong HIV production.

 

 

References

1.Yatvin, M.B. Medical Hypothesis 27,163-165 (1988)

2. Geelen, J.L.M.C. J. gen. Virol. 69, 2913-2917 (1988),

3. Stanley, S.K. et al. J of Immunology 4, 1120-1126 (1990)

4. Yatvin, M.B. Selective Cancer Therapeutics 7, 23-28 (1991)

5. Yatvin, M.B. AIDS Patient Care 6, 232-236 (1992)

6. Yatvin, M.B. et al. AIDS Patient Care 7, 5-9 (1993)

7, Yatvin, M.B. et al. Oncology 50, 380-389 (1993)

8. Chun T.W. et al. Nat Med 1, 1284-1290 (1995)

9. Chun T.W. et al. Proc Natl Acad Sci 94, 13193–13197 (1997)

10. Wong J.K. et al. Science 278, 1291–1295 (1997)

11. Finzi D. et al. Science 278, 1295–1300 (1997)

12. Finzi D. et al. Nat Med 5, 512–517 (1999)

13. Suvernev et al, 11th Inter. Cong. of Hyperthermic Oncol. Aug. 8, 2012, Kyoto Japan

14. Davey R.T. et al. PNAS 96, 15109–15114 (1999)

15. Pockley, A.G. Review The Lancet Published online April 29, 2003

16. Basu, S. et al. Internat Immunology 12, 1549-1546 (2000)

17. Anderson K.M. And Srivastava P.K. Immunol Lett 74, 35-39 (2000).

18. Basu and Srivastava Cell Stress Chapter 5, 443-451 (2000)

19. Srivastava P.K. et al. Nat Review Immunol 2, 185-194 (2002)

20. Dowd K.A. et al. PLoS pathogens 7, 1-14 (2011)

 

 

 

May 15, 2015


Yatvin and colleagues cite their 1988 paper in Medical Hypothesis that proposed hyperthermic treatment. Shortly thereafter, having had little success in getting my AmFAR grant renewed, I proposed what some now call the "kick and kill" approach to a HIV cure in Medical Hypothesis (1991) 34, 24-27 (see

http://post.queensu.ca/~forsdyke/aids.htm). We are all grateful to David Horrobin (1939-2003) for his editorship of Medical Hypothesis in those difficult years.

Popular Now

  1. A Newly Identified Species Represents Its Own Eukaryotic Lineage
  2. Telomere Length and Childhood Stress Don’t Always Correlate
  3. Research Links Gut Health to Neurodegeneration
    The Nutshell Research Links Gut Health to Neurodegeneration

    Rodent studies presented at the Society for Neuroscience meeting this week tie pathologies in the gastrointestinal tract or microbiome composition with Parkinson’s and Alzheimer’s diseases.

  4. Running on Empty
    Features Running on Empty

    Regularly taking breaks from eating—for hours or days—can trigger changes both expected, such as in metabolic dynamics and inflammation, and surprising, as in immune system function and cancer progression.

RayBiotech